Emerging nanotaxanes for cancer therapy

The clinical application of taxane (including paclitaxel, docetaxel, and cabazitaxel)-based formulations is significantly impeded by their off-target distribution, unsatisfactory release, and acquired resistance/metastasis. Recent decades have witnessed a dramatic progress in the development of high-efficiency, low-toxicity nanotaxanes via the use of novel biomaterials and nanoparticulate drug delivery systems (nano-DDSs). Thus, in this review, the achievements of nanotaxanes?targeted delivery and stimuli-responsive nano-DDSs?in preclinical or clinical trials have been outlined. Then, emerging nanotherapeutics against tumor resistance and metastasis have been overviewed, with a particular emphasis on synergistic therapy strategies (e.g., combination with surgery, chemotherapy, radiotherapy, biotherapy, immunotherapy, gas therapy, phototherapy, and multitherapy). Finally, the latest oral nanotaxanes have been briefly discussed.

Automated summary

The clinical application of taxane-based formulations faces challenges such as off-target distribution, unsatisfactory release, and resistance/metastasis. However, recent advances in nanotaxanes and nano-DDSs have shown promise in targeted delivery and combating tumor resistance and metastasis through synergistic therapy strategies. Further research on oral nanotaxanes is also being explored for potential benefits.